This Clinical Study is to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), and Preliminary Antitumor Activity of BD200 in Participants With Advanced or Metastatic Cancer.

计划入组 110 人 · 首次发布于 2026 年 9 月 1 日

BT200 in Hereditary Bleeding Disorders

计划入组 26 人 · 首次发布于 2020 年 12 月 21 日

A SAD/MAD Study of Safety, Tolerability and Pharmacologic Activity of BT200 in Normal Volunteers

计划入组 112 人 · 首次发布于 2019 年 9 月 25 日

MD200

BT200

BV200

Biolojic Design's AI-Designed BD200 Shows Superior Anti-Tumor Activity in Preclinical Studies Targeting Dual Cancer Antigens